Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

INmune Bio, Inc. INMB

Healthcare  —  Biotechnology
2.03 0.03 1.50% as of 25 Sep
Market cap
$55.5M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

INmune Bio, Inc. (INMB) Business Profile

Updated before January 2025

Company Overview

INmune Bio, Inc. (NASDAQ: INMB) is a clinical-stage biotechnology company focused on developing innovative immunotherapies to treat cancer and neurodegenerative diseases. Founded in 2015, the company is headquartered in Boca Raton, Florida, with additional operations in La Jolla, California. INmune Bio was co-founded by Dr. Raymond J. Tesi, who serves as the Chief Executive Officer, and Dr. Mark Lowdell, the Chief Scientific Officer. The leadership team is composed of seasoned professionals with extensive experience in immunology, oncology, and drug development, driving the company’s mission to harness the power of the immune system to combat life-threatening diseases.

Core Business Segments

Cancer Immunotherapy

INmune Bio’s cancer immunotherapy segment focuses on developing treatments that enhance the body’s innate immune response to fight cancer. The company’s flagship product in this category is INKmune, a novel therapy designed to activate natural killer (NK) cells to target and destroy cancer cells. INKmune is currently being evaluated in clinical trials for its efficacy in treating solid tumors and hematologic malignancies.

Neurodegenerative Diseases

The company is also pioneering treatments for neurodegenerative diseases such as Alzheimer’s disease. Its lead product in this segment, XPro1595, is a next-generation Tumor Necrosis Factor (TNF) inhibitor. Unlike traditional TNF inhibitors, XPro1595 selectively targets soluble TNF, which is implicated in neuroinflammation and neurodegeneration. This precision approach aims to reduce inflammation in the brain without compromising the immune system’s ability to fight infections.

Other Therapeutic Areas

INmune Bio is exploring additional therapeutic areas where its proprietary immunotherapy platforms can be applied. These include autoimmune diseases and other chronic inflammatory conditions. The company’s pipeline reflects its commitment to addressing unmet medical needs through innovative science.

Business Model

INmune Bio operates on a research-driven business model that integrates cutting-edge science with strategic partnerships to advance its pipeline. The company generates revenue primarily through licensing agreements, collaborations, and milestone payments from pharmaceutical partners. By focusing on early-stage clinical development, INmune Bio aims to de-risk its programs before seeking partnerships for late-stage development and commercialization. This approach allows the company to maintain a lean operational structure while maximizing the value of its intellectual property.

Strategic Direction

INmune Bio’s strategic direction is centered on expanding its clinical pipeline, advancing its existing programs, and exploring new therapeutic indications. Key priorities include:

  • Clinical Development: Accelerating the development of INKmune and XPro1595 through Phase II and Phase III clinical trials.
  • Partnerships: Establishing collaborations with leading pharmaceutical companies to co-develop and commercialize its therapies.
  • Innovation: Investing in research to identify new applications for its immunotherapy platforms.
  • Sustainability: Incorporating environmentally sustainable practices in its operations and supply chain.

The company is also exploring the potential of artificial intelligence and machine learning to enhance drug discovery and development processes.

Competitive Landscape

INmune Bio operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Cancer Immunotherapy: Companies like Kite Pharma (a Gilead company), Novartis, and Adaptimmune are developing therapies targeting NK cells and other immune pathways.
  • Neurodegenerative Diseases: Biogen, Eli Lilly, and Roche are among the major players developing treatments for Alzheimer’s and other neurodegenerative conditions.
  • TNF Inhibitors: Established TNF inhibitors such as Humira (AbbVie) and Enbrel (Amgen) dominate the market, although INmune Bio’s selective approach offers a differentiated mechanism of action.

Despite the competition, INmune Bio’s focus on innate immunity and its proprietary platforms provide a unique value proposition.

Risk Factors

Like any biotechnology company, INmune Bio faces several risks, including:

  • Clinical Trial Risks: The success of the company’s pipeline depends on the outcomes of clinical trials, which are inherently uncertain.
  • Regulatory Risks: Delays or failures in obtaining regulatory approvals could impact the company’s ability to commercialize its products.
  • Market Dependence: The company’s financial performance is heavily reliant on the success of its lead programs, INKmune and XPro1595.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers exposes the company to potential disruptions.
  • Competition: The biotechnology sector is highly competitive, with rapid advancements that could render INmune Bio’s technologies obsolete.

Recent Developments

INmune Bio has made significant progress in advancing its pipeline and corporate strategy. Recent highlights include:

  • Clinical Trials: Positive interim results from Phase I trials of INKmune in patients with advanced solid tumors.
  • Regulatory Milestones: FDA clearance to proceed with Phase II trials of XPro1595 for Alzheimer’s disease.
  • Corporate Partnerships: A strategic collaboration with a leading pharmaceutical company to explore combination therapies.
  • Global Developments: The COVID-19 pandemic underscored the importance of immunotherapy, boosting interest in INmune Bio’s platforms.

These developments position the company for continued growth and innovation.

Investment Considerations

Strengths

  • Innovative Pipeline: A robust pipeline targeting high-value therapeutic areas.
  • Experienced Leadership: A management team with deep expertise in immunology and drug development.
  • Differentiated Approach: Unique focus on innate immunity and selective TNF inhibition.
  • Strategic Partnerships: Collaborations with industry leaders to accelerate development.

Risks

  • Early-Stage Company: Limited revenue and dependence on external funding.
  • Clinical and Regulatory Risks: Uncertainty surrounding trial outcomes and approvals.
  • Market Competition: Intense competition from established players and emerging technologies.

Conclusion

INmune Bio, Inc. is at the forefront of immunotherapy innovation, leveraging its expertise in innate immunity to develop transformative treatments for cancer and neurodegenerative diseases. While the company faces inherent risks associated with early-stage biotechnology, its differentiated approach, strong leadership, and strategic direction position it as a compelling player in the sector. With a focus on advancing its pipeline and forging strategic partnerships, INmune Bio is well-positioned for future growth and value creation.